Analysis of RNA Polymerase II Mutants using Roche´s xCELLigence System

The C-terminal domain (CTD) of RNA Polymerase II consists of multiple repeats of an evolutionary conserved motif of seven amino acids, forming a repetitive structure of 52 repeats in humans and 26 repeats in yeast. Twenty years after the first description of the RNA polymerase II C-terminal domain, its function is still unclear. In a recent research study, M. Heidemann used Roche´s (Pink Sheets: RHHBY) (SWX:RO) (SWX:ROG) xCELLigence RTCA SP Instrument for in vitro testing of cells to test entirely synthetic CTDs. According to his findings, the new xCELLigence System technology allows for the first time the monitoring of cell proliferation and cell death throughout the entire experiment, constantly recording cellular effects during cell plating, transfection, and compound treatment. This non-invasive and continuous monitoring of cells provides a far more detailed picture into the whole experimental process, revealing both specific and off-target effects that may have been missed using conventional endpoint assays.

The precise regulation of gene expression is a very important feature of how organisms respond to environmental changes and regulate cell proliferation, development, and even programmed cell death. Gene expression starts with the transcription of genomic DNA into messenger RNA, the template for protein synthesis during ribosomal translation. RNA polymerase Pol II is one out of three different RNA polymerases used by eukaryotic cells to produce the main categories of cellular RNA. In contrast to Pol I and Pol III, Pol II transcripts are translated into proteins. Pol II is also modified by enzymes influencing different stages of transcription, processing of premature mRNAs in a promoter-dependent manner. These modifications occur in a domain at the carboxy-terminal part of the largest subunit of Pol II, which has a very unique structure.

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Reference
Heidemann M (2009). “Analysis of RNA Polymerase II Mutants using the xCELLigences System.” Roche Focus Application Note.

All trademarks used or mentioned in this release are protected by law.

XCELLIGENCE is a trademark of Roche.